Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01434667 · ClinicalTrials.gov registry record · NA
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 146
- Enrollment target
NCT01434667 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 146 participants.
The verdict
NCT01434667, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 146 participants
- Enrollment target
Study Summary
This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).
Interventions
- BEHAVIORAL APOE genotype and Alzheimer's disease risk disclosure
- BEHAVIORAL Alzheimer's disease risk disclosure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01434667
The ClinicalTrials.gov registry entry for NCT01434667 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which APOE genotype and Alzheimer's disease risk disclosure is the first listed.
NCT01434667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01434667 about?
NCT01434667 is a clinical study titled "Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV". This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).
What is the current status of trial NCT01434667?
This trial is currently completed. It is a NA study. The enrollment target is 146 participants. The study started on 2010-01. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01434667?
The interventions under investigation include: APOE genotype and Alzheimer's disease risk disclosure (BEHAVIORAL), Alzheimer's disease risk disclosure (BEHAVIORAL).
Who is sponsoring clinical trial NCT01434667?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.